BRPI0411944A - anticorpos humanos especìficos - Google Patents

anticorpos humanos especìficos

Info

Publication number
BRPI0411944A
BRPI0411944A BRPI0411944-4A BRPI0411944A BRPI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A BR PI0411944 A BRPI0411944 A BR PI0411944A
Authority
BR
Brazil
Prior art keywords
present
antibodies
antibody
administering
agent
Prior art date
Application number
BRPI0411944-4A
Other languages
English (en)
Inventor
Daniel Plaksin
Avigdor Levanon
Esther Szanton
Yocheved Hagay
Rachel Ben-Levy
Yariv Kanfi
Tikva Vogel
Tuvia Peretz
Lena Cooperman
Boaz Amit
Tall Szrajber
Original Assignee
Bio Technology General Israel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Israel filed Critical Bio Technology General Israel
Publication of BRPI0411944A publication Critical patent/BRPI0411944A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

"ANTICORPOS HUMANOS ESPECìFICOS". A presente invenção fornece anticorpos que se ligam a um epitopo do PSGL-1 que consiste no motivo D-X-Y-D, em que X representa qualquer aminoácido ou a ligação co-valente entre D e Y, e Y é sulfatado, o anticorpo pode ser complexado com uma ou mais cópias de um agente. Os anticorpos da invenção podem ser usados em um método de indução de citotoxicidade de célula dependente de anticorpo e/ou estímulo de células assassinas naturais (NK) ou células T. Além disso, administrando esses anticorpos a um paciente necessitado, é fornecido um método de indução à morte da célula. Também é fornecido um método de prevenção de infecção por um vírus (por ex., HIV), administrando a um paciente um anticorpo da presente invenção. A presente invenção também fornece um método de introdução de um agente em uma célula que expresse PSGL-1 sulfatado, unindo ou complexando um agente a um anticorpo da presente invenção e administrando o complexo à célula. Por fim, a presente invenção fornece métodos de diagnósticos, prognóstico e estadiamento usando os anticorpos presentes.
BRPI0411944-4A 2003-06-30 2004-06-30 anticorpos humanos especìficos BRPI0411944A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61084003A 2003-06-30 2003-06-30
PCT/US2004/021099 WO2005005455A2 (en) 2003-06-30 2004-06-30 Specific human antibodies

Publications (1)

Publication Number Publication Date
BRPI0411944A true BRPI0411944A (pt) 2007-01-02

Family

ID=34062326

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411944-4A BRPI0411944A (pt) 2003-06-30 2004-06-30 anticorpos humanos especìficos

Country Status (11)

Country Link
EP (1) EP1646401A4 (pt)
JP (1) JP2007527393A (pt)
KR (1) KR20060107501A (pt)
CN (1) CN1897970A (pt)
AU (1) AU2004256113A1 (pt)
BR (1) BRPI0411944A (pt)
CA (1) CA2531283A1 (pt)
IL (1) IL172511A0 (pt)
MX (1) MXPA06000253A (pt)
RU (1) RU2006102571A (pt)
WO (1) WO2005005455A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160601A1 (en) * 2005-12-09 2007-07-12 Angela Widom Neutralizing antibodies against primate psgl-1 and uses therefor
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
FR2894983B1 (fr) * 2005-12-16 2012-08-17 Lab Francais Du Fractionnement Test de caracterisation des anticorps.
SG188136A1 (en) * 2007-09-13 2013-03-28 Delenex Therapeutics Ag HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
WO2009099741A1 (en) 2008-02-01 2009-08-13 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
EP2303332B1 (en) 2008-07-15 2014-12-31 Genentech, Inc. Anthracycline conjugates, process for their preparation and their use as antitumor compounds
AU2012271845B2 (en) 2011-06-13 2017-07-27 Altrubio Inc. Anti-PSGL-1 antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406867B1 (en) * 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
EP1399180A4 (en) * 2000-02-29 2004-04-07 Progenics Pharm Inc CCR5 SULPHATE PEPTIDES FOR THE TREATMENT OF HIV-1 INFECTION
CA2433227A1 (en) * 2000-12-29 2002-08-01 Bio-Technology General, Inc. Specific human antibodies for selective cancer therapy
BR0116764A (pt) * 2000-12-29 2007-01-09 Savient Pharmaceuticals Inc moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos

Also Published As

Publication number Publication date
EP1646401A2 (en) 2006-04-19
RU2006102571A (ru) 2007-08-20
KR20060107501A (ko) 2006-10-13
EP1646401A4 (en) 2007-07-18
JP2007527393A (ja) 2007-09-27
CN1897970A (zh) 2007-01-17
IL172511A0 (en) 2006-04-10
CA2531283A1 (en) 2005-01-20
WO2005005455A3 (en) 2006-02-16
MXPA06000253A (es) 2007-03-08
AU2004256113A1 (en) 2005-01-20
WO2005005455A2 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
BR0313336A (pt) Chupeta para ser usada na boca de um usuário
Hecht et al. Predominance of hemoglobin Gower 1 in early human embryonic development
HUP0300951A2 (hu) Etilén-dicisztein(EC)-drog-konjugátumok, készítmények és eljárások betegség szövetspecifikus leképzésére
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
Cahan et al. Sialyloligosaccharide receptors of binding variants of polyoma virus
BRPI0411944A (pt) anticorpos humanos especìficos
Pallavi et al. Hepatitis-A: Review on Current and Future Scenario
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
Michel Self-cure in infections of Trichostrongylus retortaeformis and its causation
BR9612422A (pt) Pseudo-partìculas virais recombinantes, composição, utilização de pseudo-partìculas, e, processo de estimulação in vitro de respostas t citotóxicas de linfócitos provenientes de indivìduos atingidos por infecções virais ou tumorais.
Raffel Bacterial hypersensitivity
BR0213656A (pt) composição, método para a obtenção de uma resposta imune à tênia, método para vacinar um mamìfero contra tênia, vacina, método para pemitir a vacinação, métodos para a redução de perda sangüìnea, para a redução do tamanho da tênia e para a redução de aflição por tênia em um paciente infectado com tênia, antìgeno recombinante sintético e antìgeno
Bernard et al. NK Cells in Protection from HIV Infection
BR0210486A (pt) Proteìna, polipeptìdeo recombinante, sequência e vetor de ácido nucleico, célula em cultura, iniciador nucleotìdico, anticorpo purificado, composições imunogênica, de vacina e farmacêutica, processo de triagem de moléculas susceptìveis de inibir o crescimento de leishmania major, utilização de uma sonda de ácido nucleico, de um ou vários inibidores de proteìnas dissulfetos isomerases e de bacitracina ou de bacitracina de zinco, método de diagnóstico in vitro de uma infecção por um parasita responsável pela leishmaniose e kit diagnóstico para a realização do método
ATE249227T1 (de) Verwendung von fucosilierten sialilierten n- acetyl-lactosamin-kohlenhydratstrukturen zur hemmung der bakteriellen adhäsion
Stone et al. Case 10-2013: a 30-year-old man with fever, myalgias, arthritis, and rash
Beck Myelomatosis presenting as dermatomyositis.
Yoeli et al. Cyclical transmission of Plasmodium berghei in the laboratory
Ogidi et al. Covid-19 vaccination: the pros and cons
Toyohama et al. Kaposi's sarcoma in a human immunodeficiency virus-negative patient treated with corticosteroid for idiopathic thrombocytopenic purpura
Violand et al. Permeabilization of Ehrlich ascites tumor cells by human serum
Tibenderana Outbreak of Marburg Virus in northwest Tanzania: Unleashing health emergency
Bergman et al. Thyroid gland
Martin et al. History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications
Al-Busadah Some aspects of calcium and magnesium metabolism in the camel calves

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.